High-Yield Preparation of American Oyster Defensin (AOD) via a Small and Acidic Fusion Tag and Its Functional Characterization

文献类型： 外文期刊

第一作者： Zhao, Qingyi

作者： Zhao, Qingyi;Yang, Na;Li, Yuanyuan;Teng, Da;Hao, Ya;Mao, Ruoyu;Wang, Jianhua;Zhao, Qingyi;Yang, Na;Li, Yuanyuan;Teng, Da;Hao, Ya;Mao, Ruoyu;Wang, Jianhua;Zhao, Qingyi;Yang, Na;Li, Yuanyuan;Teng, Da;Hao, Ya;Mao, Ruoyu;Wang, Jianhua;Gu, Xinxi;Lu, Haiqiang

作者机构：

关键词： antimicrobial peptides; American Oyster Defensin (AOD); small fusion tag; pharmacodynamics; antimicrobial mechanism

期刊名称：MARINE DRUGS （ 影响因子：5.4； 五年影响因子：5.5 ）

ISSN：

年卷期： 2024 年 22 卷 1 期

页码：

收录情况： SCI

摘要： The marine peptide, American oyster defensin (AOD), is derived from Crassostrea virginica and exhibits a potent bactericidal effect. However, recombinant preparation has not been achieved due to the high charge and hydrophobicity. Although the traditional fusion tags such as Trx and SUMO shield the effects of target peptides on the host, their large molecular weight (12-20 kDa) leads to the yields lower than 20% of the fusion protein. In this study, a short and acidic fusion tag was employed with a compact structure of only 1 kDa. Following 72 h of induction in a 5 L fermenter, the supernatant exhibited a total protein concentration of 587 mg/L. The recombinant AOD was subsequently purified through affinity chromatography and enterokinase cleavage, resulting in the final yield of 216 mg/L and a purity exceeding 93%. The minimum inhibitory concentrations (MICs) of AOD against Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus galactis ranged from 4 to 8 mu g/mL. Moreover, time-killing curves indicated that AOD achieved a bactericidal rate of 99.9% against the clinical strain S. epidermidis G-81 within 0.5 h at concentrations of 2x and 4x MIC. Additionally, the activity of AOD was unchanged after treatment with artificial gastric fluid and intestinal fluid for 4 h. Biocompatibility testing demonstrated that AOD, at a concentration of 128 mu g/mL, exhibited a hemolysis rate of less than 0.5% and a cell survival rate of over 83%. Furthermore, AOD's in vivo therapeutic efficacy against mouse subcutaneous abscess revealed its capability to restrain bacterial proliferation and reduce bacterial load, surpassing that of antibiotic lincomycin. These findings indicate AOD's potential for clinical usage.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序